Long-Term Assessment of Thin-Strut BioMime Coronary Stent System in Real-World Population at Single-Center: A Retrospective Observational Study

Background: The short-term clinical outcomes of first-generation thicker-strut durable polymer-based drug-eluting stents (DES) have been widely examined. However, there is a scarcity on qualitative research on the long-term usage of DES that evaluated the thinner strut biodegradable stents for coronary artery disease. Hence, we sought to investigate the long-term safety and performance of thinner strut bio-degradable polymer-based BioMime sirolimus-eluting coronary stent system in real-world patients with symptomatic ischemic heart disease.Methods: This was a retrospective, observational, single-center, post-marketing clinical follow-up study. The primary endpoints were the incidence of major adverse cardiac events (MACEs), defined as a composite of cardiac death, myocardial infarction (MI) attributed to target vessel revascularization (TVR), and target lesion revascu-larization (TLR) at 1-, 2-, 3-and 4-year follow-ups. The secondary endpoints were cardiac death, MI, TLR, TVR, device and procedural success rates, and stent thrombosis (ST).Results: In all, 1,188 consecutive patients were enrolled, and 1,333 (1,257 de novo and 76 in-stent restenotic lesions) out of 1,565 lesions were treated with the study device. The mean age of patients was 53.26 +/- 10.31 years and 86.2% were male. The quantitative coronary angio-graphic derived mean lesion length and diameter were 29.62 +/- 9.62 mm and 3.01 +/- 0.29 mm, respectively. The average length and diameter of the study device implanted were 30.89 +/- 6.31 mm and 3.17 +/- 0.25 mm, respectively. The cumulative incidence of MACE at 1, 2, 3, and 4 years was 0.61%, 1.47%, 2.08%, and 3.40%, respectively, and cumulative deaths due to cardiac causes were 0.61%, 1.13%, 1.22%, and 1.83%, respectively. There were no cases of TLR or TVR at 1-year follow-up. The cumulative rate of TLR at 2, 3, and 4 years was 0.35%, 0.87%, and 1.57%, respectively, while that of TVR was 0.61%, 1.47%, and 2.35%, respectively. Three (0.3%) incidences of probable ST occurred during the 6-month follow-up; no new cases were reported further. In sub-group analysis, MACEs were comparable across the long-and short-length stent groups through 4-year follow-up.Conclusions: This long-term study demonstrates the safety and per-formance of the ultra-thin BioMime sirolimus-eluting stent with satis-factory clinical outcomes in patients with symptomatic ischemic heart disease in real-world scenario.